Similarly, in H1703 NSCLC cells with PDGFRA amplification that are moderately sensitive/resistant to imatinib, bypass RTK activation is suppressed by prednisolone (Supplementary Fig. 15), and prednisone plus imatinib synergistically block tumor growth (Fig. 6b). The gene discussed is PDGFRA; the disease is neoplasm.